Reports received by FDA, by month

March 2006: adverse event reports received by FDA

19,072 drug reports (FAERS) and 10,283 device reports (MAUDE).

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

19,072
drug reports received: 19,968 a year earlier; 19,264
monthly average, preceding 12 months: -1% against the average; 10,283
device reports received: 7,662 a year earlier

FDA received 19,072 drug adverse event reports in March 2006, against 19,968 in the same month a year earlier and a monthly average of 19,264 over the preceding 12 months. The MAUDE device database received 10,283 reports that month (7,662 a year earlier).

The drugs listed most often as suspect products were Vioxx (3,079), Boniva (934) and Requip (335), and the reactions recorded most often were myocardial infarction (1,846), cerebrovascular accident (1,364) and nausea (756).

Relative to their own average over the preceding 12 months, the drugs whose report count rose most were Requip (16.5× its average), Nicorette (15.8× its average) and Boniva (9.1× its average). A jump in one month usually reflects a batch of reports from a manufacturer, a publicised event or a new product, not a change in what happens to patients.

Drug reports by month, three years to March 2006

Drugs listed most often as suspect products

Drug	Reports	Share of the month
Vioxx	3,079	16.1%
Boniva	934	4.9%
Requip	335	1.8%
Accutane	332	1.7%
Remicade	297	1.6%
Tiotropium bromide	286	1.5%
Nicotine polacrilex	256	1.3%
Avonex	253	1.3%
Monistat-1 Vag Oint 6 5%	250	1.3%
Nicorette	241	1.3%
Bextra	206	1.1%
Lipitor	192	1%
Forteo	191	1%
Zyprexa	187	1%
Peg-Intron	186	1%

FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Largest rises against their own average

Drug	Reports this month	Times its 12-month average
Requip	335	16.5×
Nicorette	241	15.8×
Boniva	934	9.1×
Isotretinoin	160	8.8×
Ambien	121	8.8×
Vagistat-1	117	7×
Accutane	332	5×
Vesicare	126	3.2×

Drugs with at least 50 reports in the month and an average of at least 10 a month over the preceding year. A rise usually reflects a batch of manufacturer reports, a publicised event or a new product.

Reactions recorded most often

MedDRA term	Reports	Share of the month
Myocardial infarctionheart attack	1,846	9.7%
Cerebrovascular accidentstroke	1,364	7.2%
Nauseafeeling sick	756	4%
Chest painchest pain	731	3.8%
Dyspnoeashortness of breath	728	3.8%
Drug ineffectivethe medicine did not work as expected	724	3.8%
Headachehead pain	630	3.3%
Hypertensionhigh blood pressure	595	3.1%
Dizzinesslight-headedness or unsteadiness	589	3.1%
Vomitingbeing sick	552	2.9%
Painpain, site not specified	527	2.8%
Depressionlow mood	523	2.7%
Astheniaweakness or lack of energy	517	2.7%
Diarrhoealoose or frequent stools	513	2.7%
Anxietyanxiety	497	2.6%

Devices named most often

Brand	Reports	Share of device reports
Taxus Express2 Paclitaxel-Eluting Coronary Stent	277	2.7%
Colleague Cx Volumetric Infusion Pump	230	2.2%
M Series	173	1.7%
Cypher Sirolimus-Eluting Coronary Stent	159	1.5%
Colleague Volumetric Infusion Pump	158	1.5%
Accu-Chek Comfort Curve	150	1.5%
Ladarvision 4000	146	1.4%
Tendril Sdx	138	1.3%
One Touch Ultra	106	1%
Colleague 3cx Volumetric Infusion Pump	101	1%

Questions about March 2006

How many adverse event reports did FDA receive in March 2006?

19,072 drug reports are in the openFDA FAERS release of 28 Sep 2026, and 10,283 device reports in the MAUDE release of 28 Sep 2026. The same month a year earlier has 19,968 drug reports.

Which drugs were listed most often?

Vioxx (3,079), Boniva (934), Requip (335), Accutane (332) and Remicade (297).

Which reactions were recorded most often?

myocardial infarction (1,846), cerebrovascular accident (1,364), nausea (756), chest pain (731) and dyspnoea (728).

Can the count for a month still change?

Yes. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Older months change little.

Does a busy month mean something happened that month?

Not by itself. The date is when FDA received the report, not when the event occurred, and volume follows manufacturer batches, product launches and publicity. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.